We open this eighth edition of the newsletter with the exciting news about our most recent publications which include the first paper from the GlobalSurg-CovidSurg study week. The paper looks at timing of surgery following SARS-CoV-2 infection and is available online today in the Anaesthesia journal. Another CovidSurg paper that considers the potential benefit of vaccination for surgical patients has been accepted for publication in BJS and the GS3 findings have been published in The Lancet. Please see further details on these publications below, alongside news on developments in our Education and Training work programme, updates on the Unit’s trials and studies, the success of a particular team member in winning the 2021 Royal College of Surgeons/Rosetrees essay prize, and a range of upcoming events. 
As always, we will be grateful to receive any items that you would like to be included in future editions of the newsletter. We look forward to hearing from you.


The first paper from the GlobalSurg-CovidSurg study week – “Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study” – has been published today in the Anaesthesia journal and is available at https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.15458 (no login required).

Congratulations to everyone who has contributed this high-quality paper which will inform better care for patients globally. The study is the largest ever prospective international surgical study (>140,000 patients, 1,674 hospitals, 116 countries) and also the largest ever scientific collaboration (>15,000 authors). Thank you to all who contributed.

Please share the PDF link with friends and colleagues and also share the link on social media.

Watch this a space for further details on the upcoming CovidSurg publication exploring the benefits of the COVID-19 vaccination for surgical patients.  

GlobalSurg3 findings in The Lancet

The GlobalSurg3 Lancet publication – Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries – is available for download at https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00001-5/fulltext

If you missed the live GS3 results webinar, you can catch up via the recording at https://youtu.be/IF9zzsnOIhY

You can also explore the GlobalSurg 3 dataset using the new interactive data explorer app cancer.globalsurg.org

Read the CovidSurg contribution to Cutting Edge – the surgical blog from BJS which considers the future of COVID secure elective surgery https://cuttingedgeblog.com/2021/02/09/guest-post-covid-secure-surgery/


GSU Education and Training programme  

It is with great pleasure that we announce the reinvigoration of the GSU Education and Training Committee. The remit of this committee will be to establish and provide direction the Unit’s expanded Education and Training strategy, driving forward our training Programmes and Centres over the coming years.  New members are expected to join the committee as it is re-established.   

The following activity has so far taken place:

  • Data analysis training delivered through the Data Centre in Ghana (January 2021) 
  • Two training sessions on ‘Spokes Management, Monitoring, and Auditing’  (February 2021). In keeping with our vision of transferring ownership and ensuring sustainability, this training was co-designed with, and delivered by, managers from our India and Nigeria hubs. 

Congratulations to James who is the winner of the 2021 Royal College of Surgeons/Rosetrees essay prize. His outstanding essay was on Reducing infection and mortality after surgery around the world during the COVID-19 pandemic and beyond‘.


CHEETAH is a phenomenal success. We currently have 65 hospitals randomised, 36 sites activated and open to recruitment, and an amazing 3848 patients in the trial so far! 

This is testament to the hard work of each and every one of you and we thank you!

Please can you reinforce to your teams that ALL abdominal cases (except C-section) should have a CHEETAH Operation Sticker and be included on the CHEETAH Register.

All subsequently eligible patients should be allocated a trial number, then be uploaded on REDCap – it is OK if they did not get what they were randomised to, but they MUST still be included in the trial processes, registered in to CHEETAH and followed up in exactly the same way.

Thank you all again for your ongoing support with CHEETAH – if we continue at these current rates, we could complete recruitment by the end of the year….

Our India Hub is running the CROCODILE study on Catastrophic Expenditure in Colorectal Cancer patients. In less than 3 months, 48 patients were enrolled from 4 hospitals, including charity and government centres. This is a new and challenging study focusing on novel Health Economics methods. Our India Hub is increasing capacity and skills within the India network to collect reliable data on patient income and cancer care-related expenditure. Exciting times ahead!

We are pleased to announce the final numbers for SurgWeek:
141,582 patients
4,975 mini-teams
1,674 hospitals
116 countries
This means that in total, across the three studies, in 2020 we enrolled the following totals:
190,621 patients
2,006 different hospitals
120 different countries



On Thursday 1st April 2021 (2pm UK time) the results from the FALCON trial will be shared with all collaborators. Please mark the date in your diary if you participated in the study. The link for the meeting will be sent the hubs in due course to share with their collaborators.

Many thanks to all who contributed to this highly successful study.  

We would love to hear from you for the next edition of the newsletter.
Please send any updates that you would like included to Tammy Dufty by the 24th March 2021
Please feel free to forward this newsletter to others that you think might be interested.



Copyright © *|CURRENT_YEAR|* *|LIST:COMPANY|*, All rights reserved.

Our mailing address is:

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.